User:Mr. Ibrahem/Pralsetinib

Mr. Ibrahem/Pralsetinib
Clinical data
Trade names	Gavreto
Other names	BLU-667
AHFS/Drugs.com	Monograph
MedlinePlus	a620057
License data	US DailyMed: Pralsetinib;
Routes of; administration	By mouth
Drug class	Tyrosine kinase inhibitor
Legal status
Legal status	US: ℞-only;
Identifiers
	IUPAC name N-[(1S)-1-[6-(4-fluoropyrazol-1-yl)pyridin-3-yl]ethyl]-1-methoxy-4-[4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]cyclohexane-1-carboxamide;
Chemical and physical data
Formula	C27H32FN9O2
Molar mass	533.612 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=CC(=NN1)NC2=NC(=NC(=C2)C)C3CCC(CC3)(C(=O)NC(C)C4=CN=C(C=C4)N5C=C(C=N5)F)OC;
	InChI InChI=1S/C27H32FN9O2/c1-16-11-22(33-23-12-17(2)35-36-23)34-25(31-16)19-7-9-27(39-4,10-8-19)26(38)32-18(3)20-5-6-24(29-13-20)37-15-21(28)14-30-37/h5-6,11-15,18-19H,7-10H2,1-4H3,(H,32,38)(H2,31,33,34,35,36)/t18-,19?,27?/m0/s1; Key:GBLBJPZSROAGMF-SIYOEGHHSA-N;

Pralsetinib, sold under the brand name Gavreto, is a medication used to treat non-small cell lung cancer (NSCLC) and thyroid cancer.^[1] It is used in advanced cases which are RET fusion-positive.^[1] It is taken by mouth.^[1]

Common side effects include constipation, high blood pressure, tiredness, muscle pain, low blood cells, liver problems, and low calcium.^[1] Other side effects may include pneumonitis, bleeding, tumor lysis syndrome, and poor wound healing.^[1] Use in pregnancy may harm the baby.^[1] It is a tyrosine kinase inhibitor.^[1]

Pralsetinib was approved for medical use in the United States in 2020.^[1] In the United States it costs about 20,100 USD per month.^[2] It is not approved for use in the United Kingdom as of 2021.^[3]

References[edit]

^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l ^m "Gavreto- pralsetinib capsule". DailyMed. 9 September 2020. Archived from the original on 28 November 2020. Retrieved 24 September 2020.
^ "Gavreto Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 29 October 2021.
^ "Pralsetinib". SPS - Specialist Pharmacy Service. 4 July 2020. Archived from the original on 29 October 2021. Retrieved 29 October 2021.

[PI2021-1] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l ^m "Gavreto- pralsetinib capsule". DailyMed. 9 September 2020. Archived from the original on 28 November 2020. Retrieved 24 September 2020.

[2] "Gavreto Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 29 October 2021.

[3] "Pralsetinib". SPS - Specialist Pharmacy Service. 4 July 2020. Archived from the original on 29 October 2021. Retrieved 29 October 2021.

[1]

[2]

[3]